Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenJeffrey S. Hyams, Robert N. Baldassano, Wallace Crandall et al.|Gastroenterology|2006Cited by 872
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Stephen B. Hanauer et al.|Gastroenterology|2016Cited by 329
Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative ColitisJeffrey S. Hyams, Anne M. Griffiths, Lakshmi Damaraju et al.|Clinical Gastroenterology and Hepatology|2011Cited by 282
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extensionJeffrey S. Hyams, Robert N. Baldassano, Thomas D. Walters et al.|Current Medical Research and Opinion|2011Cited by 109
A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative ColitisJeffrey S. Hyams, Anne M. Griffiths, Lakshmi Damaraju et al.|Gastroenterology|2011Cited by 2